

KRA-533 biochemical

KRA-533

CATALOG #
AAA227417

PRODUCT SYNONYMS

KRA-533; ALN-AT3SC; SAR439774; KRA-533 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	10161-87-2
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	KRA-533 (0~30 mg/kg; 28 days) suppresses tumor growth in a dose-dependent manner in lung cancer mutant KRAS xenografts and induces apoptosis and autophagy in tumor tissues in a dose-dependent manner[1]. KRA-533 shows optimal therapeutic index between 7.5 mg/kg and 30 mg/kg doses[1]. Animal Model: Nu/Nu nude mice[1]. Dosage: 0~30 mg/kg. Administration: I.p. Result: Suppressed tumor growth in a dose-dependent manner in lung cancer mutant KRAS xenografts and induced apoptosis and autophagy in tumor tissues in a dose-dependent manner.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Fitusiran, CAS 1499251-18-1



Structure
Fitusiran, CAS 1499251-18-1

ADDITIONAL INFORMATION

Related Product Information for KRA-533 biochemical	KRA-533 is a potent KRAS agonist. KRA-533 binds to the GTP/GDP binding pocket in the KRAS protein to prevent GTP cleavage, resulting in the accumulation of constitutively active GTP-bound KRAS that triggers both apoptotic and autophagic cell death pathways in cancer cells.
References	1. Pasi KJ, et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort. J Thromb Haemost. 2021;19(6):1436-1446.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://www.aaabiotech.com/biochemical/kra-533/227417>